Transaction overview
According to a Form 4 filing with the Securities and Exchange Commission, Jorey Chernett, identified as a 10 percent owner of Oncology Institute, Inc. (NASDAQ:TOI), purchased 50,000 shares of common stock on March 26, 2026. The purchase was executed across multiple tranches at prices ranging from $3.11 to $3.19 per share, yielding an aggregate transaction value of $157,500 based on an average price of $3.15.
Following the reported trades, Chernett's direct ownership in Oncology Institute stands at 10,451,929 shares. The filing does not provide further detail on intended holding period or whether additional acquisitions or dispositions are planned.
Recent corporate performance
The insider purchase coincides with the company’s release of fourth-quarter 2025 financial results. Oncology Institute reported an earnings per share (EPS) loss of $0.06 for the quarter, which was better than the consensus estimate of a $0.09 loss. That gap equates to a positive surprise of 33.33 percent relative to the expected EPS figure. For the same period, revenue came in at $141.96 million versus a forecast of $139.79 million, delivering a modest upside to sales expectations.
Market reaction followed the earnings announcement, with the company’s stock rising in aftermarket trading. The filing indicates analysts had anticipated weaker results than those reported.
Market context and valuation signals
Despite the recent earnings beat, the stock has shown mixed performance in different time frames: it has declined about 7 percent over the prior week but remains approximately 179 percent higher compared with its level one year earlier. According to InvestingPro analysis cited in the filing, TOI appears overvalued relative to its Fair Value. At the same time, sell-side analysts collectively maintain a consensus Buy rating on the shares, with reported price targets ranging from $5 to $8.
What the record shows
The public filings supply the numerical details of the insider purchase and the company’s quarterly beats. They do not, however, include commentary from the insider or updated guidance from the company. Readers should note that the ownership data and performance metrics above are reported figures from the Form 4 and the company’s earnings release.